Abbott’s new self-expanding TAVR system gains CE mark approval

Michael Walter | | Cardiovascular Business | TAVR
approved approval

Abbott announced May 17 that the company has gained CE mark approval for its Navitor transcatheter aortic valve replacement (TAVR) system. As a result, TAVR with the self-expanding Navitor system is now available to high-risk patients with severe aortic stenosis in Europe.

Navitor was designed using Abbott’s FlexNav delivery system and the company’s NaviSeal technology for reducing the risk of a paravalvular leak.

“The innovative design of the Navitor valve paired with the FlexNav delivery system streamlines and simplifies TAVR procedures for physicians, enabling better valve placement and performance for patients so they can get back to living fuller, healthier lives,” Michael Dale, senior vice president of Abbott's structural heart business, said in a prepared statement. “This approval strengthens our structural heart portfolio of minimally invasive offerings by providing new options and improvements to treat a life-threatening heart condition.”

“With an aging world population and with aortic stenosis cases projected to double in Europe and the U.S. in the next few decades, the need for innovative, minimally invasive solutions is critical,” added Lars Sondergaard, MD, a cardiologist at Copenhagen University Hospital in Denmark. “While transcatheter valve replacement has for some time been a standard of care for patients with a narrowing of the aortic valve, Navitor helps to address challenges we sometimes find in current TAVR systems when we encounter complex patient anatomies that can lead to potential complications.”

The Navitor TAVR system and FlexNav delivery system are both approved for investigational use only in the United States.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

FDA clears AI-powered software for real-time TAVR guidance
Myval TAVR valve associated with positive durability data after 4 years
New TAVR valve from MiRus linked to positive early outcomes
Cusp overlap technique improves TAVR outcomes, new meta-analysis confirms
At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference

Around the web

Health Exec
Major association of physicians presents itself as a go-to alternative vs. the government on vaccine expertise

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations. 

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.